非布司他在治疗痛风这方面疗效如何？

How effective is febuxostat (febuxostat, feburic) in the treatment of gout? This 5-year study evaluated the uric acid-lowering effectiveness and safety of febuxostat (febuxostat, feburic) in long-term treatment of patients with gout. The primary efficacy endpoint is the reduction or maintenance of blood uric acid levels <6.0 mg/dL.

Patients after the completion of the previous 28-day study were included in an open-label extension study, with 80 mg/d febuxostat (febuxostat, feburic) as the starting dose. The dose of febuxostat (febuxostat, feburic) can be adjusted to 40 or 120 mg/day between weeks 4 and 24. All patients received treatment to prevent gout attacks during the first 4 weeks. During the entire study, gout attacks were recorded and treated, and serum uric acid (sUA), baseline tophi, and safety were monitored.

Of the 116 patients initially enrolled, 44 had dose adjustments. Finally, 8 patients received febuxostat (febuxostat, feburic) 40 mg, 79 patients received 80 mg, and 29 patients received 120 mg maintenance therapy. Of the patients still on the study after 5 years, 93% achieved sUA <6.0 mg/dL. Fifty-eight cases discontinued medication prematurely, and 38 cases discontinued medication in the first year. Thirteen patients withdrew due to adverse events. Maintenance of sUA is associated with resolution of gout attacks. Of the 26 patients who had tophi at baseline, 69% had dissolved tophi at the last follow-up visit (any time during the study, the final visit). No deaths were reported throughout the study.

Long-term treatment with febuxostat (febuxostat, feburic) brings long-term maintenance of sUA <6.0mg/dL in most patients. Patients who completed the study were virtually free of gout attacks. Most patients also have dissolution of their tophi.